These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 3315603)

  • 1. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
    Hoffmann JJ; Bonnier JJ; de Swart JB; Custers P; Vijgen M
    Drugs; 1987; 33 Suppl 3():242-6. PubMed ID: 3315602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES; Cregeen RJ
    Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
    Bonnier HJ; Visser RF; Klomps HC; Hoffmann HJ
    Am J Cardiol; 1988 Jul; 62(1):25-30. PubMed ID: 3289357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Samama M; Conard J; Verdy E; van Dreden P; Nguyen G; Combrisson A; Acar J
    Drugs; 1987; 33 Suppl 3():268-74. PubMed ID: 3315605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
    Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
    J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
    Taeymans Y; Materne P
    Drugs; 1987; 33 Suppl 3():216-20. PubMed ID: 3315594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States.
    Anderson JL
    Drugs; 1987; 33 Suppl 3():154-62. PubMed ID: 3315584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction.
    Bonnier JJ
    Drugs; 1987; 33 Suppl 3():151-3. PubMed ID: 3315583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():247-52. PubMed ID: 2445540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Kaspar L; Karnik R; Sehnal E; Zajicek P; Ziegler B; Slany J
    Drugs; 1987; 33 Suppl 3():179-82. PubMed ID: 3315588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.
    Brochier ML; Quilliet L; Kulbertus H; Materne P; Letac B; Cribier A; Monassier JP; Sacrez A; Favier JP
    Drugs; 1987; 33 Suppl 3():140-5. PubMed ID: 3315581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.
    Marder VJ; Kinsella PA; Brown MJ
    Drugs; 1987; 33 Suppl 3():237-41. PubMed ID: 3315601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
    Monnier P; Sigwart U; Vincent A; Bachmann F; Goy JJ; Schaller MD; Kaufmann U; Badan M; Grbic M; Perret C
    Drugs; 1987; 33 Suppl 3():175-8. PubMed ID: 3315587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
    Seabra-Gomes R; Aniceto Silva J; Aleixo A; Real T; Freire I; Torres I; Freitas R; Crespo F
    Drugs; 1987; 33 Suppl 3():169-74. PubMed ID: 3315586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
    Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS
    Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
    [No Abstract]   [Full Text] [Related]  

  • 19. Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Menlove RL; Anderson JL
    Drugs; 1987; 33 Suppl 3():198-208. PubMed ID: 3315592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction.
    Col JJ; Col-De Beys CM; Renkin JP; Lavenne-Pardonge EM; Bachy JL; Moriau MH
    Am J Cardiol; 1989 May; 63(17):1185-92. PubMed ID: 2653017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.